Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Core Insights - Solid Biosciences Inc. is presenting data on its proprietary capsid AAV-SLB101 and cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists Forum from December 8-10, 2025 [1][2] - The company aims to showcase the potential of its precision genetic approach to treat cardiac diseases, emphasizing the benefits of AAV-SLB101 [3][6] - Key personnel, including Dr. Gabriel Brooks and Dr. Nicolas Christoforou, will deliver presentations and participate in panel discussions at the forum [1][5][6] Company Overview - Solid Biosciences focuses on developing precision genetic medicines targeting rare neuromuscular and cardiac diseases, with a diverse pipeline including candidates for Duchenne muscular dystrophy and catecholaminergic polymorphic ventricular tachycardia [8] - The company is committed to advancing innovative genetic regulators and technologies to enhance gene therapy delivery across the industry [8] - Founded by individuals affected by Duchenne, Solid's mission is to improve the lives of patients with rare diseases [8]